Compare Merck & Co., Inc. (MRK) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Palantir Technologies Inc — how do they compare? Merck & Co., Inc. trades at $147.7 (market cap $363.98B), while Palantir Technologies Inc trades at $168.13 (market cap $407.39B). The key difference: Merck & Co., Inc. and Palantir Technologies Inc are close in size by market cap, and Merck & Co., Inc. pays a 2.3% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| MRK | PLTR | |
|---|---|---|
Market Cap | $363.98B | $407.39B |
Sector | Health | Technology |
52-Week High | $156.43 | $207.18 |
52-Week Low | $77.60 | $107.27 |
Enterprise Value | $410.75B | $398.19B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company reported strong 2025 results with $65.01B revenue and $18.25B net income, though Q1 and Q2 2026 show losses. Recent acquisition of Terns Pharmaceuticals for $6.7B aims to bolster its oncology pipeline. Analyst consensus is strongly bullish with 67.6% buy ratings and a $157 price target, representing 5.7% upside.
Merck presents a compelling investment case with solid fundamentals and strategic acquisitions, but faces risks from patent expirations and competitive pressures. The stock offers moderate upside potential with institutional support, though investors should monitor execution of growth initiatives and pipeline developments in the competitive pharmaceutical landscape.
Palantir (PLTR) trades at $170.30, down 2.31% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamental momentum, with Q2 2026 EPS of $0.41 beating expectations by 19%, and revenue growth accelerating to 93% year-over-year. Recent news highlights a strategic partnership with Nebius for sovereign AI infrastructure, positioning the company in a high-growth niche. Valuation ratios remain elevated, with a P/E of 144.9 and P/S of 70.81, reflecting high growth expectations.
The outlook for PLTR is positive due to robust earnings beats and expanding AI adoption, but risks include rich valuations and competitive pressures. Analyst consensus is bullish with a $211.38 price target, though high multiples require sustained execution. Investors should weigh growth potential against valuation sensitivity and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
